Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Q2/23 net losses earnings, cash positions and runway outcomes

August 18, 2023 4:09pm

LPS (loss-per-share) releases will present challenges to share pricing with outcomes included

8/14 - Solid Biosciences (SLDB) a net loss of -$24.6 M or -$1.25 per share with a cash position of $160.2 M and a runway until 2025

EPS concensus and revenue miss

8/14 Homology Medicine (FIXX) a net loss of -$35 M or -$0.61 per share with a cash position of $127.1 M and a runway until 2026 and seeking strategic alternatives from Cowen

closed up +$0.01

8/14 - Brainstorm Cell Therapeutics (BCLI)a net loss of -$5.3 M or -$0.13 per share with a cash position of $.75 M (?) and a runway until Q4/23

closed up +$0.05

8/14 - Harvard Apparatus (HRGN) - fomerly Biostage (BSTG)a net loss of -$2.6 M or -$0.43 per share with a cash position of $4.7 M and a runway until Q4/23

closed flat $0.00

See More … Results

Earnings season has begun ... watch your portfolio as LPS (loss-per-share), concensus and revenue "numbers" can lower your sector company negatively ...

8/10 – Adverum Biotechnologies (ADVM) – a net loss of -$31.5 M or -$0.31 per share with a cash position of $141.5 M and a runway until 2025

Closed down -$0.02

8/10 – Verve Therapeutics (VERV) – a net loss of -$85 M or -$0.60 per share with a cash position of $2.48 B and a runway until 2026

EPS consensus and revenue beat
Closed up +$0.478/9 –

8/9 - Ionis Pharmaceuticals (IONS) had a Q2/23 net loss of -$85 M or -$0.60 per share with a $2.4 B cash position and a runway until 2026

EPS consensus and revenue beat
Closed up +$0.43

8/9 – Precigen (PGEN) had a Q2/23 net loss of -$20.3 M or -$0.08 per share with a $95.6 M cash position and a runway until 2025

Closed up +$0.02

8/8 – BioLife Solutions (BLFS) had a Q2/23 net loss of -$10.2 M or -$0.23 per share with a $48.1 cash position and a runway until 2H/2025

EPS consensus and revenue miss

8/8 – Fate Therapeutics (FATE) had a Q2/23 net loss of -$56.29 M or -$0.54 per share with a $385 M cash position and a runway until 2025

EPS consensus beat and revenue miss

8/8 – Sangamo Therapeutics (FATE) had a Q2/23 net loss of -$114.5 M or -$0.66 per share with a $182.1 M cash position and a runway until 2025

EPS consensus and revenue miss

8/8 – Caribou Biosciences (CRBU) had a Q2/23 net loss of -$29.5 M or -$0.48 per share with a $293.5 M cash position (added $25 M from PFE in June) and a runway until Q4/2025

8/8 – Agenus (AGEN) had a Q2/23 net loss of -$73.4 M or -$0.20 per share with a $157.6 M cash position (received $25 m from PFE in June) and a runway until Q4/2025

Consensus EPS and revenue beat

8/8 – bluebird bio (BLUE) had a Q2/23 net loss of -$72.98 M or -$0.67 per share with a $291 M cash position (received $25 m from PFE in June) and a runway until Q4/2024

Consensus EPS and revenue beat

8/8 – Beam Therapeutics (BEAM) had a Q2/23 net loss of -$82.8 M or -$1.08 per share with a $1.1 B cash position and a runway until 2025

Consensus EPS and revenue beat

8/7 – Prime Medicine (PRMC) – a net loss of -$42.4 M or -$0.47 per share with a cash position of $221.1 M and a runway until 2024

closed down -$1.19

8/7 – AxoGen (AXGN) – a net loss of -$6.66 M or -$0.16 per share with a cash position of $23.2 M and a runway until 2025

closed down -$0.14

8/7 – CRISPR Therapeutics (CRSP) – a net loss of -$77.7 M or -$0.98 per share with a cash position of $1,843 M and a runway until 2026

closed down -$2.62

8/7 – Sage Therapeutics (SAGE) – a net loss of -$160.3 M or -$2.68 per share with a cash position of $1 B and a runway until 2025

Net loss, per-share consensus and revenue misses
share ricing drop of -$19.35

8/3 - Voyager Therapeutics (VYGR) had a Q2/23 net loss of -$22.2 M or -$0.51 per share with a $272.7 M cash position and a runway until 2026

EPS beat and revenue estimates
closed up +$0.31

8/3 - Alnylam Pharmaceuticals (ALNY) had a Q2/23 net loss of -$276 M or -$2.21 per share with a $206 B cash position and a solid runway

Missed EPS and revenue estimates
closed up +$3.09

8/3 - Compass Therapeutics (CMPS) had a Q2/23 net loss of -$11.3 M or -$0.09 per share with a $169 M cash position and a 2026 runway

Beat Q2/22 EPS and no revenue
closed up +$0.04

8/3 - Intellia Therapeutics (NTLA) had a Q2/23 net loss of -$123.7 M or -$1.40 per share with a $1.1 B cash position and a 2025 runway

Missed EPS and revenue estimates
closed down -$0.62

8/3 - Ultragenyx Pharmaceuticals (RARE) had a Q2/23 new loss of $159.8 M or -2.25 per share with a $618.4 M and a runway until 2026

Missed EPS and revenue beat
closed down -$1.05/2 -

8/3 - Cellectis SA (CLLS) had a Q2/23 consolidated net loss of -$18.6 M or -0.36 per share with a $89 M cash position and a runway until Q3/24

closed down -$0.10

8/2 - Vericel (VCEL) had a Q2/23 net loss of -$5 M or -$0.11 per share with a $147 M cash position and a runway until 2026

Surpassed EPS and revenue estimates8/2 - Blueprint Medicine (BPMC) had a Q2/23 net loss of $32.8 m or -$2.19 per share with a cash position of $1,0785.7 M and a runway until 2025

EPS surprise and tops revenue estimate

8/2 - Editas Medicine (EDIT) had a Q2/23 net loss of -$40.29 M or -$0.50 with $480 M cash position and a runway until 2025

EPS beat and revenue miss

8/2 - REGENXBIO (RGNX) had a Q2/23 net loss of -$72.1 m or -$1.66 per share with a $415 M cash position and a runway until 2025

EPS miss and lower revenue numbers
Closed down -$0.25

8/1 - UniQure NV (QURE) – a net loss of -$68.5 M or -$1.44 per share with a cash position of $628.6 M (excluded $100 M from Hemgenix, and $400 M from royalty sale) and a runway until 02.26

Per-share net loss consensus and revenue misses

8/1 - MiMedx (MDXG) - a net income of +$1.2 M or +$0.00 pre share with a cash position of $68.7 M (L-T Debt of $48.8 M) and runway until 1/24

Beats income, per share and revenue "numbers"

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.